ADME Profiling of Antibody-Drug Conjugates

Waters-Logo

Antibody biotherapeutics are an increasingly interesting area of research in the pharmaceutical industry. One area which has seen a lot of interest is ADCs or Antibody-Drug Conjugates. These drugs are antibodies that are typically used to target a tumor, or specific cells, with a “payload” that delivers the drug agent to destroy the tumor once inside the cell. The benefits of this type of treatment include fewer side effects or fewer doses.

Analyzing these conjugates is more challenging than studying just the antibody or the small molecule payload alone.  This is partially due to the added complexities of understanding the ratio of conjugates, confirming that they are bound to the appropriate location, and confirming that the correct versions have been synthesized. In addition to characterizing the structure of the ADC, understanding the pharmacokinetics, ADME properties and consequently the pharmacokinetic/pharmacodynamic properties of ADCs is critical for their successful development.

In this webcast, we will discuss the workflows that are being employed to measure and profile ADCs, and describe the tools and techniques that are being successfully deployed in this growing area.

What will you learn?

  • Steps to development of a quantitative and qualitative analytical platform for ADCs
  • Real-life examples of workflows and strategies for ADME profiling of ADCs
  • Considerations when choosing LC-MS technologies for ADC profiling

Who attended:

  • Pharmaceutical Scientists and Laboratory Managers focused on bioanalysis of small and large molecules, and antibody–drug conjugate

Speaker

HANS_WEBINARmay
Xiaogang (Sean) Han
Senior Principle Scientist
Department of Pharmacokinetics, Dynamics and Metabolism
Pfizer, Inc

Dr Han is currently senior principle scientist at Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer. As the head of LC/MS lab, he is responsible for the bioanalytical and ADME support for ADC portfolio of Pfizer Oncology Research Unit.  Prior to this, he worked at PKDM, Amgen for four years. Since his PhD training at Ecole Polytechnique, France, in biophysics, he worked in analytical and ADME area for more than 12 years.